Moderna’s Coronavirus Vaccine Shows Nearly 95 Per Cent Effective

The vaccine appears to be 94.5% effective according to preliminary data from research

Moderna's Coronavirus Vaccine Shows Nearly 95 Per Cent Effective


US Biotech Company, Moderna has recently announced that its upcoming coronavirus vaccine offers almost 95 per cent protection from the deadly disease. The results were from early research, and the company said it was a great day. The company is planning to get approval for the vaccine in the next few weeks post a successful trial.


Before announcing the 94.5 per cent effectiveness of the coronavirus vaccine, the company did a trial on 30,000 people, half of which were given two doses of the vaccine at a gap of four weeks while the other half were given a placebo. The analysis looked at the first 95 for people who developed COVID-19 symptoms. Only 5 out of the 95 had those symptoms while 90 cases occurred in people who were given the dummy vaccine. The company also shared that 11 of the cases were severe, but thankfully none of them was among the people who were given the vaccine.


Talking about the coronavirus vaccine, the Chief Medical Officer at Moderna, Tal Zaks, said “The overall effectiveness has been remarkable… it’s a great day.” There is no word on how long the immunity will last as volunteers need to be followed up for a long period before gathering any data.

Moderna’s positive news comes a week after Pfizer and BioNTech COVID vaccine trial success was announced. They tested it on 43, 500 people in six nations without detecting any safety concerns. Just 94 people in the trial developed COVID-19. The companies are seeking emergency approval to roll the vaccine, and it can be done by the end of the year.


One thing that makes Moderna’s coronavirus vaccine better than the Pfizer and BioNTech COVID vaccine is that it can be stored for a month in the refrigerator. In contrast, Pfizer’s shot must be stored in special containers and needs dry ice. Moderna hopes to ready 20 million doses of its two-shot coronavirus vaccine by the end of this year.


After the positive coronavirus vaccine news, the shares of Moderna Inc. increased 16 per cent in pre-market trade, which clearly shows how desperate the world is for a vaccine.


Share this on social media